NYSEMKT: KAPAKairos Pharma Ltd Stock Ownership - Who owns Kairos Pharma?
Insider buying vs selling
Have Kairos Pharma Ltd insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ramachandran Murali | VP of Research and Development | 2024-11-25 | 200 | $1.59 | $318.00Buy |
| Doug Samuelson | Chief Financial Officer | 2024-11-22 | 2,500 | $1.50 | $3.75kBuy |
| John S. Yu | CEO and Chairman | 2024-11-20 | 4,000 | $1.44 | $5.76kBuy |
KAPA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when KAPA insiders and whales buy or sell their stock.
KAPA Shareholders
What type of owners hold Kairos Pharma Ltd stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| John S. Yu | 32.08% | 5,355,838 | $4.34M | Insider |
| Neil Bhowmick | 6.83% | 1,139,983 | $924.53k | Insider |
| Umb Bank Na | 2.22% | 371,115 | $300.97k | Institution |
| Ramachandran Murali | 0.88% | 147,057 | $119.26k | Insider |
| Doug Samuelson | 0.36% | 60,796 | $49.31k | Insider |
| Hyun W. Bae | 0.27% | 44,286 | $35.92k | Insider |
| Rahul Singhvi | 0.18% | 30,120 | $24.43k | Insider |
| Virtu Financial LLC | 0.08% | 13,656 | $11.08k | Institution |
| Citadel Advisors LLC | 0.07% | 10,969 | $8.90k | Institution |
| Ubs Group Ag | 0.06% | 10,845 | $8.80k | Institution |
KAPA vs Biotech Stocks
Kairos Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.